Current Assets

AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value

Moderna AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Fair Value decreased by 33.3% to $2.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 81.8%, from $11.00M to $2.00M.

Analysis

StatementBalance Sheet Statement
SectionCurrent Assets
First reportedQ4 2018
Last reportedQ1 2026May 1, 2026
Metric ID: afs_trading_securities_unrealized_loss_12m_plus_fv

Historical Data

18 periods
 Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Value$0.00$0.00$21.00M$176.00M$223.00M$289.00M$289.00M$254.00M$147.00M$114.00M$85.00M$33.00M$22.00M$11.00M$7.00M$5.00M$3.00M$2.00M
QoQ Change+738.1%+26.7%+29.6%+0.0%-12.1%-42.1%-22.4%-25.4%-61.2%-33.3%-50.0%-36.4%-28.6%-40.0%-33.3%
YoY Change>999%+44.3%-34.1%-60.6%-70.6%-87.0%-85.0%-90.4%-91.8%-84.8%-86.4%-81.8%
Range$0.00$289.00M
Avg YoY Growth+45.7%
Median YoY Growth-83.3%
Current Streak11 quarters decline

Frequently Asked Questions

What is Moderna's afs and trading securities - unrealized loss position (>=12 months) fair value?
Moderna (MRNA) reported afs and trading securities - unrealized loss position (>=12 months) fair value of $2.00M in Q1 2026.
How has Moderna's afs and trading securities - unrealized loss position (>=12 months) fair value changed year-over-year?
Moderna's afs and trading securities - unrealized loss position (>=12 months) fair value decreased by 81.8% year-over-year, from $11.00M to $2.00M.